Complete mucosal healing defined by endoscopic Mayo subscore still demonstrates abnormalities by novel high definition colonoscopy and refined histological gradings

Marietta Iacucci; Miriam Fort Gasia; Cesare Hassan; Remo Panaccione; Gilaad G. Kaplan; Subrata Ghosh; Xianyong Gui

doi:10.1055/s-0034-1391863

Endoscopy, Table of Contents

Endoscopy 2015; 47(08): 726-734
DOI: 10.1055/s-0034-1391863

Original article

Complete mucosal healing defined by endoscopic Mayo subscore still demonstrates abnormalities by novel high definition colonoscopy and refined histological gradings

Marietta Iacucci

¹IBD Clinic, Division of Gastroenterology, University of Calgary, Alberta, Canada

,

Miriam Fort Gasia

¹IBD Clinic, Division of Gastroenterology, University of Calgary, Alberta, Canada

,

Cesare Hassan

²Department of Gastroenterology, Nuova Regina Margherita, Rome, Italy

,

Remo Panaccione

¹IBD Clinic, Division of Gastroenterology, University of Calgary, Alberta, Canada

,

Gilaad G. Kaplan

¹IBD Clinic, Division of Gastroenterology, University of Calgary, Alberta, Canada

,

Subrata Ghosh^*

¹IBD Clinic, Division of Gastroenterology, University of Calgary, Alberta, Canada

,

Xianyong Gui^*

³Department of Pathology and Laboratory Medicine, University of Calgary, Alberta, Canada

› Author Affiliations

Abstract

Background and study aims: A novel high definition colonoscopy imaging technique (i-Scan) can characterize, in detail, colonic mucosa in patients with ulcerative colitis, and may provide additional information about mucosal healing. The aim of this study was to create a more refined histological and endoscopic criteria based on this novel technique in order to redefine inflammatory activity and mucosal healing.

Patients and methods: A total of 78 patients with ulcerative colitis were assessed by high definition colonoscopy as well as by white light endoscopy (WLE). Mayo endoscopic subscores were assigned to patients according to WLE findings. Mucosal and vascular patterns on high definition colonoscopy were each graded from 1 – 4. A histological scoring system (ECAP system) was designed to reflect all histological changes in ulcerative colitis.

Results: The overall high definition imaging scores (mucosal and vascular patterns) were significantly correlated with Mayo endoscopic subscores (rs = 0.86, 95 % confidence interval [CI] 0.79 – 0.91; P < 0.0001). Of those with Mayo endoscopic subscore of 0, 30.4 % had an abnormal mucosal pattern and 73.9 % of them had an abnormal vascular pattern on high definition colonoscopy; a score of 6 or less had a sensitivity of 95.8 % (95 %CI 85.7 % – 99.3 %) and specificity of 75.9 % (95 %CI 56.5 % – 90.0 %) to detect mucosal healing as defined by Mayo endoscopy subscore of 0 or 1. Furthermore, mucosal and vascular pattern scores were also significantly correlated with most parameters of the proposed ECAP score.

Conclusion: The subtle histological abnormalities underlying the apparently healed mucosa in ulcerative colitis could be detected using high definition colonoscopy and the refined ECAP histology scoring system. These techniques detect residual abnormalities in the majority of patients with seemingly complete mucosal healing by conventional Mayo criteria.

Full Text

References

References
1 Travis SP, Higgins PD, Orchard T et al. Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther 2011; 34: 113-124
2 Carbonnel F, Lavergne A, Lemann M et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci 1994; 39: 1550-1557
3 Korelitz BI. Mucosal healing as an index of colitis activity: back to histological healing for future indices. Inflamm Bowel Dis 2010; 16: 1628-1630
4 Barreiro-de Acosta M, Lorenzo A, Mera J et al. Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitis. J Crohns Colitis 2009; 3: 271-276
5 Baert F, Moortgat L, Van Assche G et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology 2010; 138: 463-468
6 Colombel JF, Rutgeerts P, Reinisch W et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141: 1194-1201
7 Rutgeerts P, Van Assche G, Sandborn WJ et al. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology 2012; 142: 1102-1111
8 Levy LC, Siegel CA. Endoscopic mucosal healing in ulcerative colitis. Aliment Pharmacol Ther 2011; 33: 1254-1255
9 Romkens TE, Kampschreur MT, Drenth JP et al. High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: results of a meta-analysis of clinical trials. Inflamm Bowel Dis 2012; 18: 2190-2198
10 Sandborn WJ, Hanauer S, Van Assche G et al. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis 2014; 8: 927-935
11 Kiesslich R, Goetz M, Hoffman A et al. New imaging techniques and opportunities in endoscopy. Nat Rev Gastroenterol Hepatol 2011; 8: 547-553
12 Iacucci M, Ghosh S. Looking beyond symptom relief: evolution of mucosal healing in inflammatory bowel disease. Therap Adv Gastroenterol 2011; 4: 129-143
13 Sauk J, Hoffman A, Anandasabapathy S et al. High-definition and filter-aided colonoscopy. Gastroenterol Clinics North Am 2010; 39: 859-881
14 Kodashima S, Fujishiro M. Novel image-enhanced endoscopy with i-scan technology. World J Gastroenterol 2010; 16: 1043-1049
15 Atkinson M, Chak A. I-Scan: chromoendoscopy without the hassle?. Dig Liver Dis 2010; 42: 18-19
16 Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; Suppl A 19: 5A-36A
17 Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New Engl J Med 1987; 317: 1625-1629
18 Travis SP, Schnell D, Krzeski P et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology 2013; 145: 987-995
19 Kudo T, Matsumoto T, Esaki M et al. Mucosal vascular pattern in ulcerative colitis: observations using narrow band imaging colonoscopy with special reference to histologic inflammation. Int J Colorectal Dis 2009; 24: 495-501
20 Esaki M, Kubokura N, Kudo T et al. Endoscopic findings under narrow band imaging colonoscopy in ulcerative colitis. Dig Endosc 2011; 23: 140-142
21 Hefti MM, Chessin DB, Harpaz NH et al. Severity of inflammation as a predictor of colectomy in patients with chronic ulcerative colitis. Dis Colon Rectum 2009; 52: 193-197
22 Neumann H, Vieth M, Gunther C et al. Virtual chromoendoscopy for prediction of severity and disease extent in patients with inflammatory bowel disease: a randomized controlled study. Inflamm Bowel Dis 2013; 19: 1935-1942
23 Rutgeerts P, Diamond RH, Bala M et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc 2006; 63: 433-442
24 Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. New Engl J Med 2010; 362: 1383-1395
25 D’Haens G, Baert F, van Assche G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 2008; 371: 660-667
26 D’Haens GR. Top-down therapy for IBD: rationale and requisite evidence. Nature Rev Gastroenterol Hepatol 2010; 7: 86-92
27 Schreiber S. Certolizumab pegol for the treatment of Crohn’s disease. Therap Adv Gastroenterol 2011; 4: 375-389
28 Sandborn WJ. Mucosal healing with infliximab: results from the active ulcerative colitis trials. Gastroenterol Hepatol 2012; 8: 117-119
29 Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. New Engl J Med 2005; 353: 2462-2476
30 Sandborn WJ, Colombel JF, D’Haens G et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 2013; 37: 204-213
31 Froslie KF, Jahnsen J, Moum BA et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-422
32 Ardizzone S, Maconi G, Russo A et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006; 55: 47-53
33 Ferrante M, Vermeire S, Fidder H et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis 2008; 2: 219-225
34 Rutter M, Saunders B, Wilkinson K et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 451-459
35 Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011; 140: 1807-1816
36 Allez M, Lemann M. Role of endoscopy in predicting the disease course in inflammatory bowel disease. World J Gastroenterol 2010; 16: 2626-2632
37 Moskowitz RL, Shepherd NA, Nicholls RJ. An assessment of inflammation in the reservoir after restorative proctocolectomy with ileoanal ileal reservoir. Int J Colorectal Dis 1986; 1: 167-174
38 Gomes P, du Boulay C, Smith CL et al. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986; 27: 92-95
39 Geboes K, Riddell R, Ost A et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000; 47: 404-409
40 Saverymuttu SH, Camilleri M, Rees H et al. Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion. Gastroenterology 1986; 90: 1121-1128
41 Odze R, Antonioli D, Peppercorn M et al. Effect of topical 5-aminosalicylic acid (5-ASA) therapy on rectal mucosal biopsy morphology in chronic ulcerative colitis. Am J Surg Pathol 1993; 17: 869-875
42 D’Haens GR, Geboes K, Peeters M et al. Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114: 262-267